comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-28 01:37:26 - browse：2343

A sign of Lilly on the top of its biotechnology center — coverage from STAT — Adobe

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： New case study details death in closely watched Alzhiemer's trial

Wikipedia

hotspot

WSS

Change Healthcare cyberattack shows risk of industry consolidation

Why is France rioting? What to know about the fatal police shooting of Nahel M

'Vaccine

'Vaccine

Readout Newsletter: Beam, Prozac, "TechBio" and more

Inside the fall of star MIT scientist David Sabatini

Wikipedia

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

ChatGPT in medicine: STAT answers readers' burning questions

5 ways to address the shortage of health care workers

Drug repurposing or repositioning? The language matters

7 people shot in DC, police say

Medical leaders decry Supreme Court decision on affirmative action

Australia's humpback populations rebound raising hopes of marine scientists

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Pfizer is about to make a big push in cancer. Will investors listen?

Apple is now the first public company to be valued at $3 trillion

Neuroscience renaissance leads to new crop of psychiatric drugs

hotspot

Australia's humpback populations rebound raising hopes of marine scientists

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

Change Healthcare cyberattack shows risk of industry consolidation

Cholera vaccine supplies dangerously low, outbreaks surging

Elisabeth Bik tackles the widespread issue of research misconduct

Wikipedia

Wikipedia

hotspot

hotspot